Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alternating FOLFOX and FOLFIRI in Older Patients With Metastatic Pancreatic Cancer
NCT05360732Phase 2Active, not recruiting
- Sponsor
- Fox Chase Cancer Center
- Start
- Apr 2022
- Primary completion
- Mar 2027
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin, folinic acid, fluorouracil and irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in pancreatic cancer (PC), sponsored by Fox Chase Cancer Center. Primary endpoint: Toxicity Profile at 2 months. Started Apr 2022; status: active, not recruiting.
02
Drugs
oxaliplatinfolinic acidfluorouracilirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05360732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05360732.